InMed Pharmaceuticals News | Press Releases

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Press Releases

InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules

June 29, 2021

InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

June 17, 2021

InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

June 9, 2021

InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

May 13, 2021

InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

May 6, 2021

InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021

May 4, 2021

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

April 28, 2021

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

April 27, 2021

InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

April 26, 2021

InMed to Participate in Upcoming Investor Conferences in April and May 2022

April 19, 2021

InMed to Present at Virtual Conferences in March 2021

March 3, 2021

InMed Announces Closing of US$4.5 Million Private Placement

February 16, 2021

InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

February 11, 2021

InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results

February 6, 2021

InMed Announces US$4.5 Million Private Placement

February 5, 2021

InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

January 19, 2021

InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

January 8, 2021

InMed to Participate at Virtual Conferences in January 2021

January 5, 2021

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

December 3, 2020

InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

November 25, 2020

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Next »

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

INM-901 for Alzheimer’s Disease
INM-089 for Age-related Macular Degeneration
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Novel Analogs

MANUFACTURING

BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media & Videos
Investor Contact

CORPORATE

Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent*

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.

CAPTCHA